What's in Sprout Pharmaceuticals, Inc's pipeline?

Sprout Pharmaceuticals, Inc has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sprout Pharmaceuticals, Inc's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sprout-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sprout Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sprout Pharmaceuticals, Inc pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
flibanserin flexible dose	flibanserin flexible dose	phase 3	Serotonin 5-HT1A receptor agonist / 5-HT2A receptor antagonist	5-HT1A receptor (agonist), 5-HT2A receptor (antagonist)	Sexual Health / Women's Health

Therapeutic area mix

Sexual Health / Women's Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Sprout Pharmaceuticals, Inc:

Cite this brief

Drug Landscape (2026). Sprout Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sprout-pharmaceuticals-inc. Accessed 2026-05-17.